The FDA has approved FoundationOne® CDx and FoundationOne Liquid CDx for use as companion diagnostics to identify patients with metastatic non–small cell lung cancer harboring BRAF V600E mutations who may benefit from treatment with the combination of encorafenib plus binimetinib.
FDA approves Braftovi-Mektovi combination for lung cancer healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
We spend a lot on over-the-counter cold and flu remedies - more than £250 million a year in the UK alone - to tackle colds and flus. But could we be wasting our money?